Holen Sie sich die Stockscreener-App
20.95
8.55%
1.65
Vorhandelsmarkt:
21.36
0.41
+1.96%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action ... - Caledonian Record
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines – MREO - GlobeNewswire Inc.
Ultragenyx Pharmaceutical Reports FDA Acceptance of IND Application for UX016 - Bitget
Ultragenyx Pharmaceutical (NASDAQ:RARE) Trading Up 8.7%Still a Buy? - MarketBeat
RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. Securitie - GuruFocus
Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND - Yahoo Finance
Holzer & Holzer, LLC Reminds Investors of April 6, 2026 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Mereo BioPharma Group plc (MREO), POMDOCTOR LIMITED (POM), and Ultragenyx Pharmaceutical Inc. (RARE) - lincolnjournal.com
RARE Deadline: RARE Investors with Losses in Excess of $100K Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit - The Malaysian Reserve
Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors - GlobeNewswire
Patient-Funded UX016 IND Clearance Might Change The Case For Investing In Ultragenyx Pharmaceutical (RARE) - Yahoo Finance
Ultragenyx Stock Gaps Down 5% Amid Weak Start and Market Concerns - Markets Mojo
Ultragenyx (RARE) Gains FDA Clearance for New Drug UX016 - GuruFocus
Investors in Ultragenyx Pharmaceutical Inc. Should Contact - GlobeNewswire
POM IMPORTANT DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages PomDoctor Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action - GlobeNewswire Inc.
RARE FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ultragenyx Pharmaceutical ... - Caledonian Record
RARE FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - GlobeNewswire Inc.
NASDAQ: RARE CLASS ACTION NOTICE - marketscreener.com
Ultragenyx gains FDA IND clearance of UX016 for GNE myopathy - MSN
Ultragenyx Investors Urged to Join Securities Fraud Lawsuit - National Today
Ultragenyx Wins FDA IND Clearance for UX016 Therapy - TipRanks
Ultragenyx Announces FDA Clearance of IND for UX016 to Treat GNE Myopathy - Minichart
Ultragenyx Pharmaceutical Inc. Announces FDA Clearance Of Investigational New Drug Application For Ux016, A Sialic Acid Prodrug For The Treatment Of GNE Myopathy - marketscreener.com
Ultragenyx (RARE) wins FDA IND clearance, plans UX016 Phase 1/2 GNE myopathy trial - Stock Titan
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy - The Manila Times
Rare muscle disease with no approved drugs gets a new trial - Stock Titan
Ultragenyx downgraded to neutral at Goldman Sachs on setrusumab data - MSN
Assenagon Asset Management S.A. Has $4.59 Million Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Securities Class Action LawsuitRGRD Law - The Daily Tribune News
RARE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Investors of Securities Class Action Deadline on April 6, 2026 - PR Newswire
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Q4 2025 earnings call transcript - MSN
Is It Time To Reconsider Ultragenyx Pharmaceutical (RARE) After Its Prolonged Share Price Slump? - Sahm
[ARS] Ultragenyx Pharmaceutical Inc. SEC Filing - Stock Titan
Ultragenyx (NASDAQ: RARE) seeks approval for 2026 equity plan and director slate - Stock Titan
ULTRAGENYX DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical ... - Caledonian Record
ULTRAGENYX DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, - GlobeNewswire
Vanguard disaggregates Ultragenyx holdings (NASDAQ: RARE) after realignment - Stock Titan
RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. - GlobeNewswire
2026-03-27 | RARE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ultragenyx Pharmaceutical Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:RARE | Press Release - Stockhouse
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming DeadlinesRARE - PR Newswire
RARE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), TELA Bio (TELA) and Nuvalent (NUVL) - The Globe and Mail
Ultragenyx Pharmaceutical (NASDAQ:RARE) Upgraded to "Strong-Buy" at Truist Financial - MarketBeat
RARE Deadline: RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit - Lelezard
Ultragenyx Pharmaceutical Stock Hits Day Low of $18.29 Amid Price Pressure - Markets Mojo
Ultragenyx Pharmaceutical Hits Day Low at $19.86 Amid Price Pressure - Markets Mojo
Ultragenyx Pharmaceutical Hits 52-Week Low at $18.29 Amidst Declining Performance - Markets Mojo
Lost Money on Ultragenyx Pharmaceutical Inc.(RARE)? Join Class A - GuruFocus
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - GlobeNewswire Inc.
RARE Investor Alert: Ultragenyx Pharmaceutical Inc. Stockholders with Large Losses Should Contact Ro - PharmiWeb.com
Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ: - GlobeNewswire
RARE Investor Alert: Ultragenyx Pharmaceutical Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit - The AI Journal
FinancialContentRARE Investor Alert: Ultragenyx Pharmaceutical Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit - FinancialContent
Ultragenyx Nears Key Inflection Point With Completed Phase 3 Gene Therapy Study in GSDIa - TipRanks
Lost Money on Ultragenyx Pharmaceutical Inc.(RARE)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - PR Newswire
RARE Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Ultragenyx Pharmaceutical Inc. Securities Lawsuit -- The Gross Law Firm - Sahm
Momentum Shift: Will Ultragenyx Pharmaceutical Inc outperform tech stocksGold Moves & Free Community Supported Trade Ideas - baoquankhu1.vn
Why Ultragenyx (RARE) Is Down 14.4% After Positive Phase 3 DTX301 Gene Therapy Results - simplywall.st
4.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):